Santaris inks RNA development pact with Shire

Denmark's Santaris has nailed down a $6.5 million upfront in a new development pact with the UK's Shire. And it will pick up another $13.5 million in near-term milestones as it wraps up early studies. The pact packages five drug programs using Santaris' LNA technology that inhibits segments of RNA that play a role in rare genetic diseases. Santaris stands to gain $72 million in milestones for each of the five drug programs. Release | Report